OncRef
Skip to newsletter content
|
LymphomaOctober 2026
0:00 / 3:35
Lymphoma — Monthly Compass
Oct 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in lymphoma this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
lymphoma updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • On October 2, 2026, the FDA approved pirtobrutinib (Jaypirca) for adults with previously untreated CLL/SLL without known 17p deletion, expanding its label to the first-line setting based on BRUIN CLL-313.
    • ESMO’s Lymphomas Living Guideline v1.2 (October 2026) signaled consolidation of CD20×CD3 bispecifics across relapsed/refractory settings with potential earlier adoption pending positive phase 3 data.
  • Important Drug Publication Updates
    • On October 11, 2026, a peer‑reviewed report described accelerated glofitamab as urgent bridging to CAR T‑cell therapy in high‑risk relapsed/refractory large B‑cell lymphoma.
  • Key Clinical Development Updates
    • Pierre Fabre announced FDA acceptance of the resubmitted BLA for tabelecleucel (tab‑cel; Ebvallo) in EBV‑positive PTLD with a PDUFA target action date of March 31, 2027, incorporating updated ALLELE data and supplemental evidence following the April 2026 Type A meeting.
    • FDA accepted for review the resubmitted BLA for Ordspono (odronextamab) in relapsed/refractory DLBCL with a February 2027 target action date, and the FDA cleared Legend Biotech’s IND for LB2501—an in vivo CD19/CD20 dual‑targeting CAR‑T for relapsed/refractory B‑cell malignancies including B‑cell NHL—enabling U.S. clinical evaluation.
  • Important Clinical Trial Publications
    • A multicenter phase II study published October 6, 2026 evaluated glofitamab plus polatuzumab‑R‑CHP in DLBCL, reporting on a combination of a CD20×CD3 bispecific with a CD79b‑ADC‑containing chemoimmunotherapy backbone.
  • Key Conference Updates
    • At ESMO 2026, epcoritamab + R‑CHOP (EPCORE DLBCL‑2) reduced the risk of progression or death by 51% versus R‑CHOP in newly diagnosed DLBCL (IPI 2–5) with manageable CRS/neurologic safety via step‑up dosing, marking the first randomized success of a bispecific plus chemotherapy in this setting.
    • ESMO featured early signals from TRS005, an anti‑CD20 MMAE‑payload ADC in transformed DLBCL (Proffered Paper 1458O), alongside emerging combinations such as pola‑R‑CHP + glofitamab.
  • Emerging Themes & Macro-Trends
    • Momentum is accelerating for T‑cell–engaging bispecifics moving into frontline DLBCL and for ADC innovation in aggressive histologies, with guideline and regulatory signals indicating near‑term standard‑of‑care pressure.
    • Off‑the‑shelf CD20×CD3 bispecifics are reducing logistical barriers versus CAR‑T and are being combined with chemo/ADC backbones to improve PFS/CR rates, while sponsors advance global filings and ESMO’s living guideline cadence accelerates practice alignment.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-10-01 and 2026-10-31 about lymphoma.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Atara Biotherapeutics and partner Pierre Fabre resubmitted the BLA for tabelecleucel (tab‑cel; Ebvallo) to the FDA for EBV‑positive post‑transplant lymphoproliferative disease, following alignment at an April 2026 FDA Type A meeting; Atara noted a revised PDUFA date would be provided when available.¹ (read more)
  • Eli Lilly’s pirtobrutinib (Jaypirca) received FDA approval on October 2, 2026, for adults with previously untreated CLL/SLL without known 17p deletion, expanding its label to the first‑line setting based on BRUIN CLL‑313.² (read more)
  • Pierre Fabre announced FDA acceptance of the resubmitted BLA for tabelecleucel in EBV+ PTLD and set a PDUFA target action date of March 31, 2027; the filing incorporated updated ALLELE data and supplemental evidence following the April 2026 Type A meeting.³ (read more)
  • Legend Biotech reported FDA clearance of its IND for LB2501, an in vivo CD19/CD20 dual‑targeting CAR‑T intended for relapsed/refractory B‑cell malignancies, including B‑cell non‑Hodgkin lymphoma, enabling U.S. clinical evaluation to proceed.⁴ (read more)
  • Regeneron disclosed that FDA accepted for review the resubmission of the BLA for Ordspono (odronextamab) in relapsed/refractory DLBCL, assigning a target action date in February 2027.⁵ (read more)
Conference
Major Conference Updates
Conference Information
  • ESMO Congress 2026, IFEMA Madrid, Madrid, Spain; October 23–27, 2026. EORTC Cutaneous Lymphoma Tumour Group (CLTG) Annual Meeting, Colosseum Berlin, Berlin, Germany; October 8–10, 2026. (read more)
  • Overall sentiment: Momentum is accelerating for T‑cell–engaging bispecifics moving earlier in DLBCL and for ADC innovation in aggressive histologies; guidelines/regulatory signals suggest near‑term standard‑of‑care pressure. (read more)
  • Theme 1: Frontline Bispecifics Reshaping DLBCL
    • Significance: First randomized success of a bispecific plus chemo in newly diagnosed DLBCL positions T‑cell redirection to challenge R‑CHOP‑based standards. (read more)
    • Mechanism insights / clinical impact: Subcutaneous, CD3×CD20 engagement with “fixed‑duration” epcoritamab + R‑CHOP (EPCORE DLBCL‑2) cut risk of progression/death by 51% vs R‑CHOP; safety consistent with known CRS/neurologic risks and manageable with step‑up dosing. Early reports of “glofitamab + pola‑R‑CHP” add mechanistic complementarity (T‑cell redirection + CD79b‑ADC cytotoxicity). (read more)
    • Patient populations affected: Newly diagnosed DLBCL with IPI 2–5; potential applicability across high‑risk molecular subsets included in EPCORE DLBCL‑2 (e.g., HGBL, FL3B). (read more)
  • Theme 2: ADC Expansion Into Aggressive B‑Cell Lymphomas
    • Significance: ADC pipelines are broadening beyond CD79b toward anti‑CD20 payloaded constructs, aiming to address transformed and refractory disease where cytotoxic intensity and outpatient feasibility matter. (read more)
    • Mechanism insights / clinical impact: TRS005 (anti‑CD20 ADC; MMAE payload) showed early safety/efficacy signals in transformed DLBCL (ESMO 1458O); pairing ADCs with T‑cell engagers (e.g., pola‑R‑CHP + glofitamab) may intensify depth of response while diversifying resistance pressure. (read more)
    • Patient populations affected: Transformed indolent B‑cell lymphomas to DLBCL after ≥2 lines; de novo high‑risk DLBCL receiving pola‑R‑CHP backbones augmented by bispecifics. (read more)
  • Theme 3: Guideline and Regulatory Tailwinds for Bispecifics
    • Significance: ESMO’s Lymphomas Living Guideline v1.2 (October 2026) and regulatory progress for odronextamab (Ordspono™) signal consolidation of bispecifics across r/r settings and potential migration earlier with positive phase 3 data. (read more)
    • Mechanism insights / clinical impact: Off‑the‑shelf CD20×CD3 agents (epcoritamab, odronextamab, glofitamab) reduce logistical barriers vs CAR‑T, enable step‑up/outpatient pathways, and are being evaluated with chemo/ADC backbones to improve PFS/CR rates. (read more)
    • Patient populations affected: r/r DLBCL and FL (regulatory/EPAR updates); newly diagnosed high‑risk DLBCL as data mature. (read more)
  • Significance
    • Expected clinical or translational readouts: Full EPCORE DLBCL‑2 efficacy/safety subsets and biomarker correlatives; additional ESMO on‑demand releases and late‑2026 congress updates. (read more)
    • Regulatory or policy implications: AbbVie/Genmab initiating global filings for epcoritamab + R‑CHOP; FDA BLA resubmission for Ordspono™ accepted with February 2027 target action date; ESMO living guideline cadence enables rapid practice alignment. (read more)
    • Potential shifts in standard of care: Frontline DLBCL could pivot toward bispecific‑augmented chemo; transformed DLBCL may gain ADC options pending confirmatory datasets. (read more)
    • Strategic implications: Prioritize combination designs (bispecific + ADC/chemo), outpatient‑friendly dosing, and access planning; prepare for competitive differentiation on CRS mitigation, fixed‑duration convenience, and high‑risk subgroup efficacy. (read more)
Publications Related to Approved Drugs
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States. A partitioned survival model comparing second-line treatments for large B cell lymphoma (LBCL) found that lisocabtagene maraleucel (liso-cel) is projected to be cost-effective compared to axicabtagene ciloleucel (axi-cel) from a US commercial payer perspective. Liso-cel was associated with an incremental gain of 0.31 quality-adjusted life-years (QALYs) at a lower cost, primarily due to reduced expenses for adverse event management and CAR-T administration. ()Phase:PHASE3
Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial. In pediatric patients with high-risk classic Hodgkin lymphoma, the addition of brentuximab vedotin to AVEPC chemotherapy improved progression-free survival (PFS) across most presentations of stage IV disease. However, this survival benefit was not observed in the specific subgroup of patients with bone marrow-only involvement, highlighting a key area for further therapeutic investigation. ()Phase:PHASE3
MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL. In the EPCORE NHL-1 study for relapsed/refractory follicular lymphoma, epcoritamab monotherapy led to rapid minimal residual disease (MRD) negativity as measured by peripheral blood and ctDNA. Achieving MRD negativity by cycle 3 was strongly correlated with prolonged progression-free survival, underscoring the value of MRD assessment to complement radiographic response and confirm deep, durable responses to this bispecific antibody. ()Phase:PHASE1, PHASE2
Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study. A genomic analysis of the ECOG-ACRIN E1910 study identified distinct molecular subtypes of B-cell acute lymphoblastic leukemia (B-ALL) that may influence the efficacy of blinatumomab when added to chemotherapy. The addition of blinatumomab was associated with improved relapse-free and overall survival for several B-ALL subtypes, including hyperdiploid, PAX5alt, and KMT2A-R, suggesting genomic profiling could help guide treatment strategies. ()Phase:PHASE3
Favorable clinical and safety outcomes independent of baseline skin disease burden in treatment-naïve blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp: a subgroup analysis of a pivotal trial. A subgroup analysis of a pivotal trial in treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) demonstrated that tagraxofusp provides significant clinical benefit regardless of the baseline burden of skin disease. Patients with both high and low skin involvement achieved similar complete response rates (58%) and favorable overall survival, supporting the use of tagraxofusp as a first-line standard-of-care therapy for all BPDCN patients. ()Phase:PHASE1, PHASE2
New Publications Related to Drugs in Clinical Trial Development
A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma. This Phase II trial evaluated the addition of glofitamab to pola-R-CHP in newly diagnosed diffuse large B-cell lymphoma (DLBCL), demonstrating a high best complete response (CR) rate of 95% and a 24-month progression-free survival (PFS) of 95%. The regimen's delayed glofitamab incorporation resulted in low rates of cytokine release syndrome (CRS) and no neurotoxicity, supporting its further evaluation as a promising therapeutic strategy. ()
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial. In transplant-eligible patients with relapsed/refractory (R/R) DLBCL, the combination of epcoritamab with R-DHAX/C salvage chemotherapy induced high overall and complete response rates (79% and 69%, respectively), enabling 55% of patients to proceed to potentially curative autologous stem cell transplantation. The regimen demonstrated durable responses and manageable safety, positioning it as an effective salvage treatment option. ()
Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial. The PROSPECT phase 2 study showed that tirabrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor, resulted in rapid and durable responses (67% overall response rate, 44% complete response rate) for patients with R/R primary central nervous system lymphoma (PCNSL). This oral monotherapy demonstrated a favorable safety profile, addressing a significant unmet need in this aggressive lymphoma subtype. ()
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. In the Phase Ib/II FELIX study, obecabtagene autoleucel (obe-cel), a CD19-directed CAR T-cell therapy, demonstrated significantly higher remission rates and longer overall survival compared to standard-of-care non-CAR T-cell therapies in adults with R/R B-cell acute lymphoblastic leukemia (B-ALL). These findings suggest obe-cel could address a critical unmet need by offering superior efficacy with an acceptable safety profile. ()
CAR-HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B-cell non-Hodgkin lymphoma. This retrospective analysis of the ELM-1 and ELM-2 studies demonstrated that the CAR-HEMATOTOX score can identify patients with R/R follicular lymphoma (FL) and DLBCL at higher risk for toxicities and significantly poorer survival outcomes when treated with the CD20xCD3 bispecific antibody odronextamab. This readily available score may serve as a valuable prognostic tool for risk stratification in clinical practice. ()
Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial. The MMUD ACCESS trial, which utilized post-transplant cyclophosphamide (PTCy) for GvHD prophylaxis, revealed a significant burden of bacterial and viral infections, particularly within the first 100 days post-transplant. These findings establish a crucial safety benchmark for future trials aimed at mitigating infection risk in the mismatched unrelated donor HCT setting. ()
Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. In a phase 3 trial for adults with Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL), a chemotherapy-free frontline regimen of ponatinib plus blinatumomab proved superior to imatinib plus chemotherapy. The targeted and immunotherapeutic approach resulted in significantly higher 24-month event-free survival (86% vs. 67%) and molecular response rates, establishing a new standard of care. ()
Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy. Pre-treatment transcriptomic profiling of patients in a phase II trial revealed that a distinct myeloid-like gene expression signature was associated with poor response to CD19 CAR T-cell therapy in R/R B-ALL. This finding warrants further investigation as a potential predictive biomarker to identify patients who may benefit from alternative or combination strategies. ()
Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study. With a median follow-up of 31 months, lisocabtagene maraleucel (liso-cel) demonstrated exceptional efficacy in Japanese patients with 2L+ R/R follicular lymphoma, achieving a 100% overall and complete response rate. The treatment showed durable responses, with an 88.9% 24-month duration of response rate and a manageable safety profile, underscoring its value as a key treatment option. ()
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL. At a 3-year follow-up, a single infusion of lisocabtagene maraleucel (liso-cel) continues to show durable efficacy in patients with third-line or later follicular lymphoma, with a 36-month progression-free survival rate of 68% and an overall survival rate of 86%. The therapy maintained a favorable long-term safety profile with decreasing rates of cytopenias and infections, confirming its role as a highly effective treatment for this population. ()
Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial. The phase 3 SUNMO trial demonstrated that the mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) regimen provides profound health-related quality of life (HRQoL) benefits over standard R-GemOx in patients with ASCT-ineligible R/R large B-cell lymphoma. Patients treated with Mosun-Pola experienced longer preservation of physical functioning and greater improvements in fatigue and lymphoma symptoms, complementing the regimen's superior clinical efficacy. ()
Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial. A rigorous analysis of diagnostic tissue from the EORTC-GELA H9 trial found that the promising biomarkers c-MET, HLA class II, and CD68 were not significantly associated with progression-free survival in early-stage classic Hodgkin lymphoma. This lack of validation suggests these markers are insufficient for implementation into clinical practice for patient risk stratification. ()
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival. With 67 months of median follow-up in the phase III GLOW study, the fixed-duration combination of ibrutinib-venetoclax continues to demonstrate superior overall and progression-free survival compared to chlorambucil-obinutuzumab for older or comorbid patients with CLL. This long-term data confirms the regimen's durable disease control and its value as an effective first-line treatment option. ()
Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N). In the Pediatric MATCH trial, the RET inhibitor selpercatinib was evaluated in young patients with RET-altered tumors, leading to a confirmed partial response in one patient with a papillary thyroid carcinoma harboring a CCDC6-RET fusion. Although the study was terminated early due to low accrual, this result highlights the potential of targeted therapy for specific genetic alterations in pediatric cancers. ()
Split intein-mediated reconstitution of regulatable CAR T-cells. This proof-of-concept study introduces a novel, regulatable CAR T-cell platform based on split intein-mediated protein trans-splicing, demonstrated with a CAR targeting CD1a for T-cell acute lymphoblastic leukemia (T-ALL). The system enables conditional and transient activation of CAR T-cells upon delivery of a soluble adaptor module, offering a promising strategy for improving the modularity and safety of CAR T-cell therapy. ()
Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use. A phase 2 trial evaluating prophylactic IFN-γ blockade with emapalumab before axicabtagene ciloleucel (axi-cel) was discontinued after the first two patients developed severe, treatment-refractory CRS and ICANS alongside excessive CAR T-cell expansion. This report serves as a critical warning against the pre-emptive use of this strategy, highlighting the risk of unanticipated and severe toxicities. ()
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. The fourth-generation BTK inhibitor rocbrutinib demonstrated promising efficacy and a favorable safety profile in a phase I study of heavily pre-treated Chinese patients with relapsed or refractory non-GCB diffuse large B-cell lymphoma. The study reported an overall response rate of 57.8% and a complete response rate of 33.3%, with higher doses showing even greater activity, supporting its continued development. ()
A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M). The NCI-COG Pediatric MATCH trial arm evaluating the farnesyl transferase inhibitor tipifarnib in children with HRAS-mutated refractory solid tumors showed limited single-agent efficacy, with no objective responses observed. While the drug's safety profile was acceptable, the study highlights the challenge of targeting this pathway in pediatric cancers and the low frequency of these mutations. ()
Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm. A phase 2 study of the triplet combination of tagraxofusp, azacitidine, and venetoclax demonstrated high activity in both newly diagnosed and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), with composite complete remission rates of 88% and 64%, respectively. The regimen had a manageable safety profile and enabled a high proportion of patients to bridge to allogeneic stem cell transplantation, establishing it as a new therapeutic option. ()
Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study. In the phase 2 DISTINKT study, the anti-PD-L1 antibody danburstotug demonstrated robust and durable efficacy in patients with relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL), achieving an objective response rate of 78.9% and a 2-year overall survival rate of 77.9%. High PD-L1 membrane specificity was associated with better outcomes, suggesting its potential as a predictive biomarker for this manageable therapy. ()
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial. The first-in-human trial of roginolisib, a novel conformation-selective PI3Kδ inhibitor, demonstrated a favorable safety profile with no dose-limiting toxicities in patients with advanced malignancies. In a cohort of heavily pre-treated metastatic uveal melanoma patients, the drug showed promising clinical activity, with a median overall survival of 20.8 months and evidence of beneficial immune modulation. ()
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial. Anbalcabtagene autoleucel, a novel CD19 CAR T-cell therapy incorporating dual PD-1 and TIGIT knockdown, demonstrated significant efficacy in a phase 1/2 study for relapsed or refractory large B-cell lymphoma, achieving a complete response rate of 67.1%. Sustained responses were associated with greater CAR T-cell expansion and reduced checkpoint expression, highlighting the potential of this next-generation immunotherapy. ()
Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826). A subset analysis of the phase 3 SWOG S1826 trial revealed that the nivolumab-AVD (N-AVD) regimen substantially improved 3-year progression-free survival and abrogated the historically poor prognosis associated with both EBV-positive status and non-nodular sclerosis histology in advanced-stage classic Hodgkin lymphoma. These findings strongly support N-AVD as a frontline standard of care, particularly for these high-risk patient subgroups. ()
Prospective phase 2 trial of high- and intermediate-intensity myeloablative conditioning for cord blood transplantation. This prospective phase 2 trial demonstrated excellent outcomes for umbilical cord blood transplantation (UCBT) following myeloablative conditioning, with a 1-year overall survival of 78%. Notably, an intermediate-intensity conditioning regimen achieved comparable results to high-intensity approaches but with encouragingly low non-relapse mortality, supporting its use as a viable strategy to reduce toxicity while preserving disease control. ()
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial. A comprehensive molecular analysis of patients in the FIL V-RBAC trial identified that beyond TP53 mutations, other genetic lesions including CDKN2A loss, CD36 mutations, and single-hit ATM abnormalities are independent predictors of survival in mantle cell lymphoma. These findings were integrated into a novel 4-factor molecular prognostic model, enabling a more precise risk assessment for older patients. ()
Feasibility and Safety of a Novel CD19-Directed CAR T-Cell Therapy in Patients with R/R B-Cell Non-Hodgkin Lymphoma. A phase 1 trial of UCD19, a novel CD19 CAR T-cell therapy incorporating a TNFRSF19 transmembrane domain, demonstrated a favorable safety profile with no grade 3 or higher CRS or ICANS in patients with R/R B-cell NHL. The therapy also showed promising preliminary efficacy, with a 90% overall response rate and a 70% complete response rate at 90 days, supporting further investigation. ()
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma. A comprehensive pharmacokinetic/pharmacodynamic (PKPD) model was successfully developed using data from four DREAMM trials to characterize the dynamic relationships between belantamab mafodotin, soluble BCMA, and M-protein in patients with relapsed/refractory multiple myeloma. This model provides a valuable tool for simulating various dosing schedules and understanding the interplay between the drug and key disease markers. ()
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States. Based on an indirect treatment comparison using data from the TRANSFORM and ZUMA-7 trials, a cost-effectiveness analysis from a US payer perspective found that lisocabtagene maraleucel (liso-cel) is a cost-effective option compared to axicabtagene ciloleucel (axi-cel) for second-line treatment of large B-cell lymphoma. Liso-cel was projected to provide slightly more quality-adjusted life-years at a lower overall cost, driven by better overall survival and lower costs for adverse event management. ()
CAR-HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B-cell non-Hodgkin lymphoma. This retrospective analysis of the ELM-1 and ELM-2 studies demonstrated that the CAR-HEMATOTOX score can identify patients with R/R follicular lymphoma (FL) and DLBCL at higher risk for toxicities and significantly poorer survival outcomes when treated with the CD20xCD3 bispecific antibody odronextamab. This readily available score may serve as a valuable prognostic tool for risk stratification in clinical practice. ()
Arginine rewires eIF4F translation initiation to overcome fever-induced CAR T cell dysfunction. A retrospective analysis linked sustained high-grade fever—a hallmark of cytokine release syndrome—with poor clinical response to CD22-directed CAR T-cell therapy. Mechanistically, hyperthermia impairs CAR T-cell function via dysregulated arginine metabolism, but supplementation with arginine was found to restore cytotoxicity and metabolic fitness, suggesting a tractable strategy to enhance therapeutic efficacy. ()
Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia. In a phase 2 study for pediatric patients with relapsed/refractory ALL, the addition of carfilzomib to a VXLD chemotherapy backbone (vincristine, dexamethasone, asparaginase, and daunorubicin) did not result in a statistically significant improvement in complete remission rates compared to an external real-world control. While the regimen may be an option for some heavily pretreated patients, the study underscores the high unmet need for more effective therapies in this population. ()
Outcome after first relapse post-immunochemotherapy in older adults with Philadelphia-negative B-cell acute lymphoblastic leukemia: A GRAALL study. The retrospective RELAPSINO study revealed that older patients with Ph- B-ALL who relapse after frontline inotuzumab-based immunochemotherapy have a dismal prognosis, with a median overall survival of only 4.5 months. However, achieving a second complete remission was possible in 51% of patients who received salvage therapy and was associated with significantly better survival, indicating that salvage attempts should be considered. ()
Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease. In a phase 1b/2 study, the combination of the ROR1-targeting antibody zilovertamab with ibrutinib was well-tolerated but did not improve response rates or progression-free survival over ibrutinib alone in the overall relapsed/refractory CLL population. However, a post-hoc analysis revealed a hypothesis-generating signal of prolonged disease control in the high-risk del(17p) subset, warranting further investigation. ()
Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study. A phase 1b study demonstrated that combining the bispecific antibody glofitamab with R-CHOP immunochemotherapy yielded promising efficacy, with a complete metabolic response rate of 83.9% in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. The combination had a manageable safety profile, supporting its further investigation in the first-line setting for diffuse large B-cell lymphoma. ()
PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study. This pilot study found that a novel graft-versus-host disease (GVHD) prophylaxis regimen incorporating RGI-2001 with PTCy, sirolimus, and MMF was feasible in the haploidentical transplant setting. The regimen successfully achieved its primary endpoint and demonstrated recovery of regulatory T-cell subsets post-HCT with acceptable rates of severe acute and chronic GVHD. ()
Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials. A pooled analysis of six clinical trials confirmed that apremilast provides significant improvements in skin clearance and quality of life for psoriasis patients with limited skin involvement (BSA 3-10%). The therapy was also effective for patients with involvement in high-impact sites such as the scalp, genital area, and nails, demonstrating its utility in this often-underserved patient population. ()
Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients. A phase I/II trial showed that the chemotherapy-free combination of subcutaneous mosunetuzumab and polatuzumab vedotin is an effective first-line treatment for older, unfit, or frail patients with DLBCL. The regimen achieved a complete response rate of 56.4% and a 2-year overall survival of 62.4% with a manageable safety profile, presenting a potential new standard for this vulnerable population. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in lymphoma updated from 2026-10-01 to 2026-10-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-12---3
Not Yet Recruiting8516-1-30
Recruiting473869321-178
Available-------
Approved for Marketing-------
Active, Not Recruiting322042420-118
Completed-12---3
Total8765131742-332
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
: anti-CD19 CAR-T cells, Cyclophosphamide, Fludarabine NCT04545762 RECRUITING A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma 2026-10-31
: MB-CART19.1 NCT03853616 ACTIVE_NOT_RECRUITING A Phase I Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies 2026-11
: Anti-ICOS Monoclonal Antibody MEDI-570 NCT02520791 ACTIVE_NOT_RECRUITING A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL) 2026-12-24
CPI-818 NCT03952078 ACTIVE_NOT_RECRUITING A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma 2026-12-30
Cyclophosphamide, Fludarabine NCT04637763 ACTIVE_NOT_RECRUITING A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) 2026-12-31
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Ponatinib 45mg OD, Ponatinib 30mg OD NCT04233346 COMPLETED A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation 2026-09-08
Ifosfamide, Nivolumab, Carboplatin, Etoposide NCT04981899 COMPLETED Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma 2026-09-15
Varlilumab, : Nivolumab NCT03038672 ACTIVE_NOT_RECRUITING A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas 2026-10-24
Pembrolizumab NCT03728972 ACTIVE_NOT_RECRUITING Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type 2026-11
Selinexor NCT02227251 ACTIVE_NOT_RECRUITING A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) 2026-12
Erdafitinib NCT03210714 ACTIVE_NOT_RECRUITING NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations 2026-12-30
Crizotinib NCT06360575 ACTIVE_NOT_RECRUITING MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion 2026-12-31
Vismodegib NCT06357988 ACTIVE_NOT_RECRUITING MATCH Treatment Subprotocol T: GDC-0449 (Vismodegib) in Patients With Tumors (Except Basal Cell Skin Carcinoma) With Smoothened (SMO) or Patched 1 (PTCH1) Mutations 2026-12-31
5-Hydroxytryptophan NCT04160910 RECRUITING 5HTP Regulation Of Asthma In Children 2026-12-31
Pegaspargase, Calaspargase Pegol, Asparaginase Erwinia chrysanthemi, Leucovorin Calcium, Vincristine, : Inotuzumab Ozogamicin, Cytarabine, Cyclophosphamide, Methotrexate NCT02981628 ACTIVE_NOT_RECRUITING A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) 2026-12-31
Venetoclax, Azacitidine NCT04128501 ACTIVE_NOT_RECRUITING A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell Leukemia, and Mixed Phenotype Acute Leukemia 2026-12-31
Prednisone, : Rituximab, Lenalidomide, Vincristine Sulfate, Doxorubicin Hydrochloride, Cyclophosphamide NCT01856192 ACTIVE_NOT_RECRUITING Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma 2026-12-31
Ulixertinib NCT06400225 ACTIVE_NOT_RECRUITING MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations 2026-12-31
Prednisone, Methotrexate, Tacrolimus, Etoposide, Dexamethasone, Leucovorin Calcium, Vincristine Sulfate, Cytarabine, Doxorubicin Hydrochloride, : Filgrastim, Cyclophosphamide, Dasatinib, Methylprednisolone, Sirolimus NCT00792948 ACTIVE_NOT_RECRUITING Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) 2027-01-06
Prednisone, Acalabrutinib, : Rituximab, Lenalidomide, Vincristine, Doxorubicin Hydrochloride, Cyclophosphamide, : Tafasitamab NCT04978584 ACTIVE_NOT_RECRUITING Smart Stop: A Phase II Trial of Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Prior to and With Standard Chemotherapy for Patients With Newly Diagnosed DLBCL 2027-01-16
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Venetoclax, : Obinutuzumab, Ibrutinib NCT03737981 ACTIVE_NOT_RECRUITING A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL) 2026-12-29
Brentuximab vedotin, Lenalidomide, Rituximab NCT04404283 ACTIVE_NOT_RECRUITING A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) 2026-12-31
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.